LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 62

Search options

  1. Article ; Online: Early Diagnosis of Acute Myocarditis or Dilated Cardiomyopathy in Children Younger Than 2 Years.

    Ahmed, Yasir / Heidemann, Sabrina M

    Pediatric emergency care

    2023  Volume 39, Issue 10, Page(s) 751–754

    Abstract: Objective: Diagnosis of acute myocarditis or dilated cardiomyopathy (DCM) on initial presentation is difficult in children younger than 2 years because most present with complaints suggestive of a respiratory infection. The objective of this study is to ...

    Abstract Objective: Diagnosis of acute myocarditis or dilated cardiomyopathy (DCM) on initial presentation is difficult in children younger than 2 years because most present with complaints suggestive of a respiratory infection. The objective of this study is to determine whether signs, symptoms, and diagnostic studies excluding those of heart failure, done routinely in the emergency department could distinguish children younger than 2 years with acute myocarditis or DCM from those with respiratory illnesses.
    Methods: Sixty-four infants' charts, 32 cases and 32 controls, were reviewed from January 1, 2009, through December 31, 2020. Controls were matched to cases with respect to age, reason, and time of admission. Signs, symptoms, and blood gases were reviewed.
    Results: The median age is 6.5 (0.5-22) months in both groups. Infants presenting with signs of heart failure including murmurs ( P = 0.002), prolonged capillary refill ( P = 0.024), cool, mottled extremities ( P = 0.002), poor perfusion ( P = 0.001), or hepatomegaly ( P < 0.001) were more likely to be diagnosed with acute myocarditis or DCM when compared with the control group with respiratory disease. Infants with fever ( P = 0.017), nasal congestion ( P < 0.001), rhinorrhea ( P < 0.001), cough ( P < 0.001), and wheezing ( P < 0.001) were more likely to have a respiratory illness than acute myocarditis or DCM. The presence of a lower p co2 (30 [14-116] vs 40 [31-59] mm Hg, P < 0.001), lower bicarbonate (16.7 [6.3-23.4] vs 21.7 [16-28.4], P < 0.001), or an oxygen saturation > 95% ( P = 0.004) was observed in infants with acute myocarditis or DCM compared with those with respiratory illness. By multivariable analysis, infants with tachycardia in the absence of fever, metabolic acidosis, and an oxygen saturation > 95% were more likely to have acute myocarditis or DCM than those without this disease.
    Conclusions: Children younger than 2 years presenting to the emergency department with tachycardia and no fever, metabolic acidosis, and a high oxygen saturation should be investigated for acute myocarditis or DCM.
    MeSH term(s) Infant ; Child ; Humans ; Myocarditis/diagnosis ; Cardiomyopathy, Dilated/diagnosis ; Cardiomyopathy, Dilated/etiology ; Heart Failure ; Early Diagnosis
    Language English
    Publishing date 2023-08-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632588-9
    ISSN 1535-1815 ; 0749-5161
    ISSN (online) 1535-1815
    ISSN 0749-5161
    DOI 10.1097/PEC.0000000000003038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2.

    Heidemann, Sabrina M / Tilford, Bradley / Bauerfeld, Christian / Martin, Amarilis / Garcia, Richard U / Yagiela, Lauren / Sarnaik, Ashok P

    The American journal of case reports

    2020  Volume 21, Page(s) e925779

    Abstract: BACKGROUND Coronavirus disease 2019 (COVID-19) infection commonly presents as fever, cough, and shortness of breath in adults. Children are thought to have milder respiratory symptoms and to recover more quickly. We describe a new presentation of COVID- ... ...

    Abstract BACKGROUND Coronavirus disease 2019 (COVID-19) infection commonly presents as fever, cough, and shortness of breath in adults. Children are thought to have milder respiratory symptoms and to recover more quickly. We describe a new presentation of COVID-19 infection in children consisting of multisystem inflammation with decreased left ventricular function and evidence of lung disease. CASE REPORT Three children presented with fever, conjunctivitis, dry and cracked lips, rash, and/or cervical lymphadenopathy for at least 5 days. Two of these children required mechanical ventilation, and 1 of the 2 needed extracorporeal membrane oxygenation (ECMO) to support cardiorespiratory function. All of these children had moderate to severe hyponatremia and lymphopenia, which is usually seen in COVID-19. They were treated with intravenous immunoglobulin and high-dose aspirin. All of the children recovered. CONCLUSIONS Early recognition of children with multisystem inflammation is important because they are at increased risk for deterioration. Treatment with intravenous immunoglobulin and aspirin was used because this regimen has been shown to be beneficial in vasculitis of Kawasaki disease. The development of shock due to cardiac involvement may require ECMO.
    MeSH term(s) Antipyretics/therapeutic use ; Aspirin/therapeutic use ; Betacoronavirus ; COVID-19 ; Child ; Child, Preschool ; Conjunctivitis/therapy ; Conjunctivitis/virology ; Coronavirus Infections/diagnosis ; Coronavirus Infections/therapy ; Exanthema/therapy ; Exanthema/virology ; Extracorporeal Membrane Oxygenation ; Female ; Fever/therapy ; Fever/virology ; Heart Failure/therapy ; Heart Failure/virology ; Humans ; Hyponatremia/therapy ; Hyponatremia/virology ; Immunoglobulins, Intravenous ; Lymphadenopathy/therapy ; Lymphadenopathy/virology ; Lymphopenia/therapy ; Lymphopenia/virology ; Male ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/therapy ; Respiration, Artificial ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome/diagnosis ; Systemic Inflammatory Response Syndrome/therapy ; Systemic Inflammatory Response Syndrome/virology ; Vasculitis/therapy ; Vasculitis/virology
    Chemical Substances Antipyretics ; Immunoglobulins, Intravenous ; Aspirin (R16CO5Y76E)
    Keywords covid19
    Language English
    Publishing date 2020-08-13
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2517183-5
    ISSN 1941-5923 ; 1941-5923
    ISSN (online) 1941-5923
    ISSN 1941-5923
    DOI 10.12659/AJCR.925779
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children.

    Heidemann, Sabrina M / Nair, Alison / Bulut, Yonca / Sapru, Anil

    Pediatric clinics of North America

    2016  Volume 64, Issue 5, Page(s) 1017–1037

    Abstract: Acute respiratory distress syndrome (ARDS) is a syndrome of noncardiogenic pulmonary edema and hypoxia that accompanies up to 30% of deaths in pediatric intensive care units. Pediatric ARDS (PARDS) is diagnosed by the presence of hypoxia, defined by ... ...

    Abstract Acute respiratory distress syndrome (ARDS) is a syndrome of noncardiogenic pulmonary edema and hypoxia that accompanies up to 30% of deaths in pediatric intensive care units. Pediatric ARDS (PARDS) is diagnosed by the presence of hypoxia, defined by oxygenation index or Pao
    MeSH term(s) Acute Disease ; Child ; Combined Modality Therapy ; Critical Care/methods ; Diet Therapy ; Extracorporeal Circulation ; Fluid Therapy/methods ; Humans ; Respiration, Artificial/adverse effects ; Respiration, Artificial/methods ; Respiratory Insufficiency/physiopathology ; Respiratory Insufficiency/therapy ; Syndrome
    Language English
    Publishing date 2016-12-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 215711-1
    ISSN 1557-8240 ; 0031-3955
    ISSN (online) 1557-8240
    ISSN 0031-3955
    DOI 10.1016/j.pcl.2017.06.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Management of Hospitalized Asthmatic Children Before Transport.

    Mazzeo, Brande / Bzeih, Rami / Schultz, Robert / Tavolieri, Melissa / Fraser, Alicia / Heidemann, Sabrina M

    Air medical journal

    2017  Volume 36, Issue 1, Page(s) 30–33

    Abstract: Asthmatic children are at risk for respiratory failure and should be appropriately treated before transport. The objectives were to find out if the Pediatric Advanced Life Support guidelines for asthma treatment were followed in the emergency department ( ...

    Abstract Asthmatic children are at risk for respiratory failure and should be appropriately treated before transport. The objectives were to find out if the Pediatric Advanced Life Support guidelines for asthma treatment were followed in the emergency department (ED); to determine if additional treatment during transport or within the first 2 hours of admission was needed; and to compare the management of intubated asthmatics by the ED, transport team, and the intensive care unit (ICU) physician. The records for children diagnosed with acute asthma over 7 years who were transported by the intensive care transport team were reviewed. The use of albuterol, steroids, oxygen, heliox, continuous positive airway pressure or bilevel positive airway pressure, and ventilator settings was recorded. Two hundred seventy-nine children were 7 years (age, 5 mo-17 y), and 62% were male. Eighty percent received oxygen, albuterol, and steroids in the ED. Heliox was initiated more often by the transport team when compared with the ED or hospital physician (77% vs. 7.7% vs. 15.3%, P < .0001). Forty-five were mechanically ventilated and were more likely to receive volume control (P < .0001) and higher rates (P = .007) in the ED than the ICU. We conclude that most children with acute asthma were treated with oxygen, albuterol, and steroids in the ED. If used, heliox was most likely started during transport. Intubated children were more likely to receive volume control with higher rates compared with lower rates and pressure control in the ICU.
    MeSH term(s) Adolescent ; Anti-Asthmatic Agents/therapeutic use ; Asthma/therapy ; Child ; Child, Preschool ; Female ; Hospitalization ; Humans ; Infant ; Male ; Respiration, Artificial ; Retrospective Studies ; Transportation of Patients/methods
    Chemical Substances Anti-Asthmatic Agents
    Language English
    Publishing date 2017-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2072853-0
    ISSN 1532-6497 ; 1067-991X
    ISSN (online) 1532-6497
    ISSN 1067-991X
    DOI 10.1016/j.amj.2016.11.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Anticoagulation practices associated with bleeding and thrombosis in pediatric extracorporeal membrane oxygenation; a multi-center secondary analysis.

    Bailly, David K / Reeder, Ron W / Muszynski, Jennifer A / Meert, Kathleen L / Ankola, Ashish A / Alexander, Peta Ma / Pollack, Murray M / Moler, Frank W / Berg, Robert A / Carcillo, Joseph / Newth, Christopher / Berger, John / Bell, Michael J / Dean, J M / Nicholson, Carol / Garcia-Filion, Pamela / Wessel, David / Heidemann, Sabrina / Doctor, Allan /
    Harrison, Rick / Dalton, Heidi / Zuppa, Athena F

    Perfusion

    2022  Volume 38, Issue 2, Page(s) 363–372

    Abstract: To determine associations between anticoagulation practices and bleeding and thrombosis during pediatric extracorporeal membrane oxygenation (ECMO), we performed a secondary analysis of prospectively collected data which included 481 children (<19 years), ...

    Abstract To determine associations between anticoagulation practices and bleeding and thrombosis during pediatric extracorporeal membrane oxygenation (ECMO), we performed a secondary analysis of prospectively collected data which included 481 children (<19 years), between January 2012 and September 2014. The primary outcome was bleeding or thrombotic events. Bleeding events included a blood product transfusion >80 ml/kg on any day, pulmonary hemorrhage, or intracranial bleeding, Thrombotic events included pulmonary emboli, intracranial clot, limb ischemia, cardiac clot, and arterial cannula or entire circuit change. Bleeding occurred in 42% of patients. Five percent of subjects thrombosed, of which 89% also bled. Daily bleeding odds were independently associated with day prior activated clotting time (ACT) (OR 1.03, 95% CI= 1.00, 1.05,
    MeSH term(s) Humans ; Child ; Extracorporeal Membrane Oxygenation/adverse effects ; Anticoagulants/adverse effects ; Hemorrhage/etiology ; Hemorrhage/therapy ; Thrombosis/etiology ; Heparin/adverse effects ; Fibrinogen ; Retrospective Studies
    Chemical Substances Anticoagulants ; Heparin (9005-49-6) ; Fibrinogen (9001-32-5)
    Language English
    Publishing date 2022-02-27
    Publishing country England
    Document type Multicenter Study ; Journal Article
    ZDB-ID 645038-6
    ISSN 1477-111X ; 0267-6591
    ISSN (online) 1477-111X
    ISSN 0267-6591
    DOI 10.1177/02676591211056562
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children.

    Chang, Joyce C / Young, Cameron C / Muscal, Eyal / Sexson Tejtel, Sara K / Newhams, Margaret M / Kucukak, Suden / Crandall, Hillary / Maddux, Aline B / Rowan, Courtney M / Halasa, Natasha B / Harvey, Helen A / Hobbs, Charlotte V / Hall, Mark W / Kong, Michele / Aguiar, Cassyanne L / Schuster, Jennifer E / Fitzgerald, Julie C / Singh, Aalok R / Wellnitz, Kari /
    Nofziger, Ryan A / Cvijanovich, Natalie Z / Mack, Elizabeth H / Schwarz, Adam J / Heidemann, Sabrina M / Newburger, Jane W / Zambrano, Laura D / Campbell, Angela P / Patel, Manish M / Randolph, Adrienne G / Son, Mary Beth F

    Arthritis & rheumatology (Hoboken, N.J.)

    2023  Volume 75, Issue 8, Page(s) 1466–1476

    Abstract: Objective: Evidence regarding effectiveness of interleukin-1 receptor antagonism in multisystem inflammatory syndrome in children (MIS-C) is lacking. We characterized variation in initial treatment with anakinra and evaluated cardiovascular outcomes ... ...

    Abstract Objective: Evidence regarding effectiveness of interleukin-1 receptor antagonism in multisystem inflammatory syndrome in children (MIS-C) is lacking. We characterized variation in initial treatment with anakinra and evaluated cardiovascular outcomes associated with adding anakinra to standard initial therapy.
    Methods: We conducted a retrospective cohort study of MIS-C cases in a US surveillance registry from November 2020 to December 2021. Day 0 was the first calendar day of immunomodulatory treatment. Factors associated with initial anakinra use (days 0-1) were identified. We compared cases in patients ages 2-20 years receiving intravenous immunoglobulin (IVIG) and glucocorticoids versus anakinra plus IVIG and/or glucocorticoids on days 0-1, using inverse probability weighting to balance disease severity. Primary outcomes were vasopressor requirement on day 3 and impaired left ventricular ejection fraction on days 3-4. The secondary outcome was 50% reduction in C-reactive protein on day 3.
    Results: Among 1,516 MIS-C cases at 44 sites, 193 (13%) patients received anakinra alone or with other immunomodulators as initial treatment (range 0-74% by site). Site accounted for 59% of residual variance in anakinra use. After balancing disease severity, initial treatment with anakinra plus IVIG and/or glucocorticoids (n = 121) versus IVIG plus glucocorticoids (n = 389) was not associated with significant differences in vasopressor requirement (25.6% versus 20.1%, respectively; risk ratio [RR] 1.27 [95% confidence interval (95% CI) 0.88-1.84]), ventricular dysfunction (33.7% versus 25.7%, respectively; RR 1.31 [95% CI 0.98-1.75]), or C-reactive protein reduction.
    Conclusion: We identified substantial variation in initial anakinra use in a real-world population of children with MIS-C, but no average short-term improvement in cardiovascular outcomes associated with early addition of anakinra to IVIG and/or glucocorticoids compared to IVIG and glucocorticoids alone.
    MeSH term(s) Child ; Humans ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Immunoglobulins, Intravenous/therapeutic use ; C-Reactive Protein ; Stroke Volume ; Retrospective Studies ; Ventricular Function, Left ; Glucocorticoids/therapeutic use ; Connective Tissue Diseases
    Chemical Substances Interleukin 1 Receptor Antagonist Protein ; Immunoglobulins, Intravenous ; C-Reactive Protein (9007-41-4) ; Glucocorticoids
    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42495
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.

    Zambrano, Laura D / Newhams, Margaret M / Simeone, Regina M / Payne, Amanda B / Wu, Michael / Orzel-Lockwood, Amber O / Halasa, Natasha B / Calixte, Jemima M / Pannaraj, Pia S / Mongkolrattanothai, Kanokporn / Boom, Julie A / Sahni, Leila C / Kamidani, Satoshi / Chiotos, Kathleen / Cameron, Melissa A / Maddux, Aline B / Irby, Katherine / Schuster, Jennifer E / Mack, Elizabeth H /
    Biggs, Austin / Coates, Bria M / Michelson, Kelly N / Bline, Katherine E / Nofziger, Ryan A / Crandall, Hillary / Hobbs, Charlotte V / Gertz, Shira J / Heidemann, Sabrina M / Bradford, Tamara T / Walker, Tracie C / Schwartz, Stephanie P / Staat, Mary Allen / Bhumbra, Samina S / Hume, Janet R / Kong, Michele / Stockwell, Melissa S / Connors, Thomas J / Cullimore, Melissa L / Flori, Heidi R / Levy, Emily R / Cvijanovich, Natalie Z / Zinter, Matt S / Maamari, Mia / Bowens, Cindy / Zerr, Danielle M / Guzman-Cottrill, Judith A / Gonzalez, Ivan / Campbell, Angela P / Randolph, Adrienne G

    MMWR. Morbidity and mortality weekly report

    2024  Volume 73, Issue 15, Page(s) 330–338

    Abstract: Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with ... ...

    Abstract Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered <120 days before hospitalization and 19% (95% CI = 2%-32%) if the interval was 120-364 days. VE of the original monovalent vaccine against COVID-19-related hospitalization was 31% (95% CI = 18%-43%) if the last dose was received any time within the previous year. VE against critical COVID-19-related illness, defined as receipt of noninvasive or invasive mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, and illness resulting in death, was 57% (95% CI = 21%-76%) when the most recent dose was received <120 days before hospitalization, 25% (95% CI = -9% to 49%) if it was received 120-364 days before hospitalization, and 38% (95% CI = 15%-55%) if the last dose was received any time within the previous year. VE was similar after excluding children and adolescents with documented immunocompromising conditions. Because of the low frequency of children who received updated COVID-19 vaccines and waning effectiveness of original monovalent doses, these data support CDC recommendations that all children and adolescents receive updated COVID-19 vaccines to protect against severe COVID-19.
    MeSH term(s) Humans ; Adolescent ; Child ; United States/epidemiology ; COVID-19 Vaccines ; COVID-19/epidemiology ; COVID-19/prevention & control ; mRNA Vaccines ; Vaccine Efficacy ; SARS-CoV-2 ; Hospitalization ; RNA, Messenger
    Chemical Substances COVID-19 Vaccines ; mRNA Vaccines ; RNA, Messenger
    Language English
    Publishing date 2024-04-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7315a2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Echocardiographic Indicators Associated with Adverse Clinical Course and Cardiac Sequelae in Multisystem Inflammatory Syndrome in Children with Coronavirus Disease 2019.

    Sanil, Yamuna / Misra, Amrit / Safa, Raya / Blake, Jennifer M / Eddine, Ahmad Charaf / Balakrishnan, Preetha / Garcia, Richard U / Taylor, Rachel / Dentel, John N / Ang, Jocelyn / Cashen, Katherine / Heidemann, Sabrina M / Bauerfield, Christian / Sethuraman, Usha / Farooqi, Ahmad / Aggarwal, Sanjeev / Singh, Gautam

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography

    2021  Volume 34, Issue 8, Page(s) 862–876

    Abstract: Background: Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 causes significant cardiovascular involvement, which can be a determinant of clinical course and outcome. The aim of this study was to investigate ...

    Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 causes significant cardiovascular involvement, which can be a determinant of clinical course and outcome. The aim of this study was to investigate whether echocardiographic measures of ventricular function were independently associated with adverse clinical course and cardiac sequelae in patients with MIS-C.
    Methods: In a longitudinal observational study of 54 patients with MIS-C (mean age, 6.8 ± 4.4 years; 46% male; 56% African American), measures of ventricular function and morphometry at initial presentation, predischarge, and at a median of 3- and 10-week follow-up were retrospectively analyzed and were compared with those in 108 age- and gender-matched normal control subjects. The magnitude of strain is expressed as an absolute value. Risk stratification for adverse clinical course and outcomes were analyzed among the tertiles of clinical and echocardiographic data using analysis of variance and univariate and multivariate regression.
    Results: Median left ventricular apical four-chamber peak longitudinal strain (LVA4LS) and left ventricular global longitudinal strain (LVGLS) at initial presentation were significantly decreased in patients with MIS-C compared with the normal cohort (16.2% and 15.1% vs 22.3% and 22.0%, respectively, P < .01). Patients in the lowest LVA4LS tertile (<13%) had significantly higher C-reactive protein and high-sensitivity troponin, need for intensive care, and need for mechanical life support as well as longer hospital length of stay compared with those in the highest tertile (>18.5%; P < .01). Initial LVA4LS and LVGLS were normal in 13 of 54 and 10 of 39 patients, respectively. There was no mortality. In multivariate regression, only LVA4LS was associated with both the need for intensive care and length of stay. At median 10-week follow-up to date, seven of 36 patients (19%) and six of 25 patients (24%) had abnormal LVA4LS and LVGLS, respectively. Initial LVA4LS < 16.2% indicated abnormal LVA4LS at follow-up with 100% sensitivity.
    Conclusion: Impaired LVGLS and LVA4LS at initial presentation independently indicate a higher risk for adverse acute clinical course and persistent subclinical left ventricular dysfunction at 10-week follow-up, suggesting that they could be applied to identify higher risk children with MIS-C.
    MeSH term(s) COVID-19/diagnosis ; COVID-19/epidemiology ; Child ; Child, Preschool ; Disease Progression ; Echocardiography/methods ; Female ; Heart Ventricles/diagnostic imaging ; Humans ; Male ; Pandemics ; Retrospective Studies ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome/diagnosis ; Systemic Inflammatory Response Syndrome/epidemiology
    Language English
    Publishing date 2021-05-03
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 1035622-8
    ISSN 1097-6795 ; 0894-7317
    ISSN (online) 1097-6795
    ISSN 0894-7317
    DOI 10.1016/j.echo.2021.04.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.

    Zambrano, Laura D / Newhams, Margaret M / Olson, Samantha M / Halasa, Natasha B / Price, Ashley M / Boom, Julie A / Sahni, Leila C / Kamidani, Satoshi / Tarquinio, Keiko M / Maddux, Aline B / Heidemann, Sabrina M / Bhumbra, Samina S / Bline, Katherine E / Nofziger, Ryan A / Hobbs, Charlotte V / Bradford, Tamara T / Cvijanovich, Natalie Z / Irby, Katherine / Mack, Elizabeth H /
    Cullimore, Melissa L / Pannaraj, Pia S / Kong, Michele / Walker, Tracie C / Gertz, Shira J / Michelson, Kelly N / Cameron, Melissa A / Chiotos, Kathleen / Maamari, Mia / Schuster, Jennifer E / Orzel, Amber O / Patel, Manish M / Campbell, Angela P / Randolph, Adrienne G

    MMWR. Morbidity and mortality weekly report

    2022  Volume 71, Issue 2, Page(s) 52–58

    Abstract: Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the ... ...

    Abstract Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),
    MeSH term(s) Adolescent ; BNT162 Vaccine/therapeutic use ; COVID-19/complications ; Case-Control Studies ; Child ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Patient Acuity ; SARS-CoV-2/immunology ; Systemic Inflammatory Response Syndrome/drug therapy ; United States/epidemiology ; Vaccine Efficacy ; COVID-19 Drug Treatment
    Chemical Substances BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-01-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7102e1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2

    Heidemann, Sabrina M / Tilford, Bradley / Bauerfeld, Christian / Martin, Amarilis / Garcia, Richard U / Yagiela, Lauren / Sarnaik, Ashok P

    Am J Case Rep

    Abstract: BACKGROUND Coronavirus disease 2019 (COVID-19) infection commonly presents as fever, cough, and shortness of breath in adults. Children are thought to have milder respiratory symptoms and to recover more quickly. We describe a new presentation of COVID- ... ...

    Abstract BACKGROUND Coronavirus disease 2019 (COVID-19) infection commonly presents as fever, cough, and shortness of breath in adults. Children are thought to have milder respiratory symptoms and to recover more quickly. We describe a new presentation of COVID-19 infection in children consisting of multisystem inflammation with decreased left ventricular function and evidence of lung disease. CASE REPORT Three children presented with fever, conjunctivitis, dry and cracked lips, rash, and/or cervical lymphadenopathy for at least 5 days. Two of these children required mechanical ventilation, and 1 of the 2 needed extracorporeal membrane oxygenation (ECMO) to support cardiorespiratory function. All of these children had moderate to severe hyponatremia and lymphopenia, which is usually seen in COVID-19. They were treated with intravenous immunoglobulin and high-dose aspirin. All of the children recovered. CONCLUSIONS Early recognition of children with multisystem inflammation is important because they are at increased risk for deterioration. Treatment with intravenous immunoglobulin and aspirin was used because this regimen has been shown to be beneficial in vasculitis of Kawasaki disease. The development of shock due to cardiac involvement may require ECMO.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #713485
    Database COVID19

    Kategorien

To top